Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM)

Facchinetti, Francesco; Pilotto, Sara; Metro, Giulio; Baldini, Editta; Bertolaccini, Luca; Cappuzzo, Federico; Delmonte, Angelo; Gasparini, Stefano; Inno, Alessandro; Marchetti, Antonio; Passiglia, Francesco; Puma, Francesco; Ricardi, Umberto; Rossi, Antonio; Crinò, Lucio; Novello, Silvia

doi:10.1177/0300891619857418

Cited by 10 publications

(7 citation statements)

References 103 publications

(148 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All Patients enrolled started a first-line immunotherapy with Pembrolizumab within three to six weeks from the baseline CECT, a humanized antibody targeting the PD-1 receptor of lymphocytes, at standard dose of 200 mg i.v. every 3 weeks according to AIOM-ESMO guidelines 17 .…”

Section: Methodsmentioning

confidence: 99%

CT based radiomic approach on first line pembrolizumab in lung cancer

Zerunian

Zucchelli

Polici

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Clinical evaluation poorly predicts outcomes in lung cancer treated with immunotherapy. The aim of the study is to assess whether CT-derived texture parameters can predict overall survival (OS) and progression-free survival (PFS) in patients with advanced non-small-cell lung cancer (NSCLC) treated with first line Pembrolizumab. Twenty-one patients with NSLC were prospectively enrolled; they underwent contrast enhanced CT (CECT) at baseline and during Pembrolizumab treatment. Response to therapy was assessed both with clinical and iRECIST criteria. Two radiologists drew a volume of interest of the tumor at baseline CECT, extracting several texture parameters. ROC curves, a univariate Kaplan-Meyer analysis and Cox proportional analysis were performed to evaluate the prognostic value of texture analysis. Twelve (57%) patients showed partial response to therapy while nine (43%) had confirmed progressive disease. Among texture parameters, mean value of positive pixels (MPP) at fine and medium filters showed an AUC of 72% and 74% respectively (P < 0.001). Kaplan-Meyer analysis showed that MPP < 56.2 were significantly associated with lower OS and PFS (P < 0.0035). Cox proportional analysis showed a significant correlation between MPP4 and OS (P = 0.0038; HR = 0.89[CI 95%:0.83,0.96]). In conclusion, MPP could be used as predictive imaging biomarkers of OS and PFS in patients with NSLC with first line immune treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

CT based radiomic approach on first line pembrolizumab in lung cancer

Zerunian

Zucchelli

Polici

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The characteristics of the CPGs are summarized in Table 1. Seven CPGs were established for SCLC (10-16), 20 for NSCLC (17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36), and 22 for lung cancer regardless of histological subtype . The number of published CPGs increased every year, with a total of 22 CPGs published in 2020.…”

Section: Characteristics Of Selected Guidelinesmentioning

confidence: 99%

Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist

Yang¹,

Lü²,

Ma³

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: In recent years, the number of clinical practice guidelines (CPGs) for lung cancer has increased, but the quality of these guidelines has not been systematically assessed so far. Our aim was to assess the reporting quality of CPGs on lung cancer published since 2018 using the International Reporting Items for Practice Guidelines in Health Care (RIGHT) instrument. Methods:We systematically searched the major electronic literature databases, guideline databases and medical society websites from January 2018 to November 2020 to identify all CPGs for small cell and nonsmall cell lung cancer (NSCLC). The search and extraction were completed using standardized forms.The quality of included guidelines was evaluated using the RIGHT statement. We present the results descriptively, including a stratification by selected determinants.Results: A total of 49 CPGs were included. The mean proportion across the guidelines of the 22 items of the RIGHT checklist that were appropriately reported was 57.9%. The items most common to be poorly reported were quality assurance (item 17) and description of the role of funders (item 18b), both of which were reported in only one guideline. The proportions of items within each of the seven domains of the RIGHT checklist that were correctly reported were Basic information 75.9%; background 83.2%; evidence 44.5%; recommendations 55.4%; review and quality assurance 12.2%; funding and declaration and management of interests 42.9%; and other information 38.1%. The reporting quality of guidelines did not differ between publication years. CPGs published in journals with impact factor >30 tended to be best reported. Conclusions:Our results revealed that reporting in CPGs for lung cancer is suboptimal. Particularly the declaration of funding and quality assurance are poorly reported in recent CPGs on lung cancer.

show abstract

“…The incidence and mortality rates of lung cancer rank first in the world . Approximately 80% of lung cancer is classified as non‐small cell lung cancer (NSCLC), and approximately 75% of patients are in the middle or advanced stage when they are diagnosed . The major treatment strategies for NSCLC are surgery and adjuvant therapy .…”

Section: Introductionmentioning

confidence: 99%

“…Approximately 80% of lung cancer is classified as non‐small cell lung cancer (NSCLC), and approximately 75% of patients are in the middle or advanced stage when they are diagnosed . The major treatment strategies for NSCLC are surgery and adjuvant therapy . However, radio‐ and drug‐resistance are still the main obstacle in clinic and the side effects of immunotherapy remain puzzled .…”

Section: Introductionmentioning

confidence: 99%

The miRNA‐149‐5p/MyD88 axis is responsible for ursolic acid‐mediated attenuation of the stemness and chemoresistance of non‐small cell lung cancer cells

Chen

Luo

et al. 2019

Environmental Toxicology

View full text Add to dashboard Cite

Although the inhibitory roles of ursolic acid (UA) have been established in various tumors, its effects on the stemness of non‐small cell lung cancer (NSCLC) cells are still unclear. Here, we constructed NSCLC cells with paclitaxel resistance (A549‐PR) and showed that A549‐PR exhibited a remarkably stronger stemness than the parental A549 cells, which is evident by the increase of spheroid formation capacity, stemness marker expression, and ALDH1 activity. Additionally, UA significantly reduced the stemness and paclitaxel resistance of A549‐PR cells. Mechanistic investigations revealed that UA inhibited the miR‐149‐5p/MyD88 signaling, which is responsible for UA‐mediated effects on the stemness of A549‐PR cells. Notably, miR‐149‐5p/MyD88 axis promoted the stemness of A549 cells, while inhibition of this axis attenuated the stemness of A549‐PR cells. Therefore, these results suggest that UA could attenuate the stemness and chemoresistance of NSCLC cells through targeting miR‐149‐5p/MyD88 axis.

show abstract

Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM)

Cited by 10 publications

References 103 publications

CT based radiomic approach on first line pembrolizumab in lung cancer

CT based radiomic approach on first line pembrolizumab in lung cancer

Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist

The miRNA‐149‐5p/MyD88 axis is responsible for ursolic acid‐mediated attenuation of the stemness and chemoresistance of non‐small cell lung cancer cells

Contact Info

Product

Resources

About